✦ LIBER ✦

Management of skin toxicity of epidermal growth factor receptor inhibitors

✍ Scribed by Siegfried Segaert

Book ID: 107384332
Publisher: Springer-Verlag
Year: 2008
Tongue: English
Weight: 192 KB
Volume: 3
Category: Article
ISSN: 1776-2596
DOI: 10.1007/s11523-008-0092-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Skin toxicities associated with epiderma

Skin toxicities associated with epidermal growth factor receptor inhibitors

✍ Tianhong Li; Roman Perez-Soler 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 288 KB

Epidermal Growth Factor Receptor Inhibit

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Nonmelanoma Skin Cancers

✍ MISBAH H. KHAN; MURAD ALAM; SIMON YOO 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB

Treatment of epidermal growth factor rec

Treatment of epidermal growth factor receptor inhibitor-induced skin toxicities: do the data support the current practice?

✍ Jonathan Cotliar 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 54 KB

Effects of epidermal growth factor recep

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life

✍ Smita S. Joshi; Sara Ortiz; Joslyn N. Witherspoon; Alfred Rademaker; Dennis P. W 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Epidermal growth factor receptor dimeriz

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies

✍ Laux, I; Jain, A; Singh, S; Agus, D B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 166 KB

Clinical implications of the mechanism o

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

✍ John Marshall 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

## Abstract Novel therapeutic agents that target the epidermal growth factor receptor (EGFR) constitute an important addition to the therapeutic armamentarium for the treatment of metastatic disease. EGFR‐targeted agents currently approved by the U.S. Food and Drug Administration include cetuximab,